CH-0601 by Caelus Health for Type 1 Diabetes (Juvenile Diabetes): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CH-0601 overview

CH-0601 is under development for the treatment of type 1 diabetes. The therapeutic candidate comprises of fecal microbiota.

Caelus Health overview

Caelus Health develops microbiome therapeutics for the treatment of cardio-metabolic diseases. The company’s pipeline portfolio offers CP-001 (E. hallii), used to decrease insulin resistance in patients with metabolic syndrome (MetS) and also helps in the prevention of type 2 diabetes (T2DM) ad is in Phase II clinical trials. It also offers CP-002 (Intestinimonas) for reducing advanced glycation endproducts (AGEs) in patients with MetS and T2DM; and CP-003 (Ralstonia Pickettii) is a vaccine for preventing T2DM and are in preclinical stage of development. The company has signed an agreement with Academisch Medisch Centrum (AMC), Amsterdam for Fecal Microbiota Transplant (FMT) studies. Caelus Health is headquartered in Amsterdam, Noord Holland, the Netherlands.

For a complete picture of CH-0601’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.